GRAIL

GRAIL's mission is to detect cancer early, when it can be cured.
Community Guidelines:
Cancer SIGNAL Podcast:

[GRAIL @GrailBio]

We will announce second quarter 2026 financial results on August 5.

Register for the webcast: https://t.co/USD8GGyatZ
Read more: https://t.co/X0pLxOdd37

[GRAIL @GrailBio]

Today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation to make GRAIL’s Galleri multi-cancer early detection (MCED) test available to Priority Health’s self-insured employer groups. Learn more: https://t.co/hsPRFOzFYz

#MCED #EarlyCancerDetection

[GRAIL @GrailBio]

Many cancers stay hidden until it is too late. When cancer is diagnosed after it has spread distantly, it is more difficult to treat and typically has worse outcomes.

Diagnosing cancer before Stage IV can make a meaningful difference. For a growing number of cancers, treatment with curative intent may still be possible at Stage III.

That’s why reducing Stage IV diagnoses remains such an important part of improving cancer outcomes.

Learn more: https://t.co/8timD9nml7

#CancerScreening #EarlyCancerDetection

[GRAIL @GrailBio]

Today GRAIL announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation. Learn more: https://t.co/Ece2jxFHXh

[GRAIL @GrailBio]

Galleri cannot replace other cancer screening tests. The Galleri test is intended to be used in addition to recommended single cancer screening tests, including screening tests for lung cancer for high-risk smokers, breast cancer, cervical cancer, colorectal cancer, and prostate cancer. Using the Galleri test alongside existing cancer screening programs, such as mammograms and colonoscopies, is expected to maximize early cancer detection. Galleri is designed to detect a signal shared by multiple cancers including many unscreened cancers.

[GRAIL @GrailBio]

In a clinical trial, the Galleri test detected a signal shared by multiple cancer types, listed here: https://t.co/WyKYRljf4W. This is a list of cancers that study participants had which were used to train the Galleri test to recognize cancer and to test the Galleri tests performance. The list of cancers is not a list of individual cancers that Galleri tests for. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. If a cancer signal is detected, then the test reports the top organ/tissue associated with the cancer signal, called Cancer Signal Origin (CSO), to help providers decide which follow-up diagnostic tests to do to confirm cancer. Please contact Customer Service by emailing [email protected] or calling 833-694-2553 for more information.

[GRAIL @GrailBio]

Melissa didn’t take a multi-cancer early detection (MCED) test once and leave it at that. She made MCED testing part of her annual health routine.

The first year, the test did not detect a cancer signal. The second year, she received a Cancer Signal Detected result with a predicted origin of liver/bile ducts. Melissa felt healthy and had no symptoms. Follow up diagnostic testing confirmed Stage I bile duct cancer.

Now she’s using her story to encourage others to keep cancer screening part of the conversation, year after year.

#CancerScreening #EarlyCancerDetection #MCED

The overall sensitivity in study participants with liver/bile duct cancer was 93.5% (100% for stage I, 70.0% stage II, 100% stage III, 100% stage IV).

Rx only. See Important Safety Information: https://t.co/qvv6PHhH4I

[GRAIL @GrailBio]

“Early detection can save an awful lot of lives, I think I’m evidence of that.”

Ann joined the NHS-Galleri trial evaluating a multi-cancer early detection (MCED) test hoping her participation might help others. She never imagined it would help her, too.

Watch her story and learn more about the NHS-Galleri trial: https://t.co/35Vkh5jFlL

The overall sensitivity in study participants with colon/rectum cancer was 82% (43.3% for stage I, 85% stage II, 87.9% stage III, 95.3% stage IV).

[GRAIL @GrailBio]

Robert signed on for the NHS-Galleri trial with the intention of advancing cancer research. When the multi-cancer early detection (MCED) test returned a Cancer Signal Detected result, he was shocked.

On the latest episode of The Cancer SIGNAL podcast, host Rayshawnda Madison speaks with Robert as he shares how his follow-up journey eventually led to an early HPV-related cancer diagnosis, what it was like to navigate treatment and recovery, and how the experience changed the way he thinks about health and early detection.

The Cancer SIGNAL is available wherever you listen to podcasts.

#EarlyCancerDetection #MCED #Podcast

Apple Podcasts: https://t.co/8SDQLf7MG3
Spotify: https://t.co/wZ2R6ZlQQT
Transcripts & more episodes: https://t.co/OFHzfRCWDe

[GRAIL @GrailBio]

Dr. Nima Nabavizadeh, principal investigator for the PATHFINDER 2 study, shares key takeaways from this data. He noted:

“As an oncologist, I have seen too many patients diagnosed only after their cancer has spread, when treatment decisions become more difficult. By helping find more cancers earlier, when more treatment options may be available, there is great potential for multi-cancer early detection to transform cancer screening.”

Find all of GRAIL’s data from #ASCO26 here: https://t.co/35Vkh5jFlL

RX Only. See Important Safety Information: https://t.co/Mx2Czka4Bj

[GRAIL @GrailBio]

PATHFINDER 2 data being presented today at #ASCO26 offer new evidence on the safety and performance of a multi-cancer early detection (MCED) test when used alongside recommended #CancerScreenings.

Review the results from the largest #MCED interventional study in North America: https://t.co/mmkvyFFMMf

RX Only. See Important Safety Information: https://t.co/Mx2Czka4Bj

[GRAIL @GrailBio]

When Doreen volunteered for the NHS-Galleri trial evaluating a multi-cancer early detection (#MCED) test, she never expected the study would identify a signal for #lymphoma in her own blood.

Follow-up testing confirmed a Stage I-II lymphoma diagnosis and Doreen was able to promptly begin treatment. Today, she’s back on her bike and sharing her journey to help others understand the importance of #EarlyCancerDetection.

See more about the NHS-Galleri trial: https://t.co/35Vkh5jFlL

#ASCO26

The overall sensitivity in study participants with lymphoma was 56.3% (27.3% for stage I, 58.3% stage II, 71.7% stage III, 60.9% stage IV).

[GRAIL @GrailBio]

Results from the NHS-Galleri trial presented at #ASCO26 found that the addition of the Galleri test to standard-of-care cancer screenings led to a four-fold increase in screen-detected cancers.

Learn more about our data from ASCO: https://t.co/35Vkh5jFlL

The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. RX Only. See Important Safety Information: https://t.co/Mx2Czka4Bj

[GRAIL @GrailBio]

Today at #ASCO26, we are presenting full results from the NHS-Galleri trial, evaluating annual multi-cancer early detection (MCED) blood testing in more than 142,000 participants across England’s National Health Service (NHS).

Review the findings: https://t.co/j2LlSK3l8G

RX Only. See Important Safety Information: https://t.co/Mx2Czka4Bj

[GRAIL @GrailBio]

Our #ASCO26 program highlights new data across #MCED testing, including detailed results from the NHS-Galleri trial, results from the PATHFINDER 2 study, and implementation insights in a private practice setting.

See more: https://t.co/qlXQZYJsQn

#EarlyCancerDetection

[GRAIL @GrailBio]

Want to stay up to date on all things GRAIL?

Sign up for our newsletter to receive updates on the work we’re doing to shape the future of early cancer detection: https://t.co/fhAaXIFdY7

#EarlyCancerDetection #CancerScreening #MCED

[GRAIL @GrailBio]

@maggie_hott @sweatystartup We are sorry to hear about this and take these reports seriously. Please contact us so we can learn more at https://t.co/BXkaBiDtTC or call 833-694-2553.

[GRAIL @GrailBio]

Today GRAIL reported first quarter 2026 financial results.

Read the press release: https://t.co/1nyT1xhw8V

[GRAIL @GrailBio]

We will announce first quarter 2026 financial results on May 5.

Register for the webcast: https://t.co/F2xjyho4en
Read more: https://t.co/eCjCvquQVW

[GRAIL @GrailBio]

At #ASCO26, we’re presenting primary results from the NHS-Galleri trial, the first randomized controlled study of an #MCED test, plus the full PATHFINDER 2 dataset.

Together, this data strengthens evidence on MCED performance, safety, and clinical utility.

📊: https://t.co/Zafr8tLQVt